TABLE 2.
Main characteristics of studies examining the association between sRAGE and the risk of mortality1
| First author/year (reference) | Country | Study design | Follow-up duration, y | Population | Age (mean or range), y | Sex | Outcome assessment | Effect measures (95% CI) | Study quality score |
|---|---|---|---|---|---|---|---|---|---|
| All-cause mortality | |||||||||
| Gros et al./2007 (49) | Netherlands | Cohort | 4.2 | Renal transplant recipients | 51 | M/F | Follow-up | HR 0.98 (0.97, 0.99) | 7 |
| Semba et al./2009 (38) | Italy | Cohort | 4.5 | Older community-dwelling women | ≥65 | F | National Death Index | HR 1.03 (0.99, 1.06) | 7 |
| Nakashima et al./2010 (43) | Sweden | Prospective case-control | 3.4 | Hemodialysis patients | 67 | M/F | NR | HR 1.00 (0.99, 1.01) | 6 |
| Nin et al./2010 (46) | Netherlands | Cohort | 12.3 | T1DM | ≥18 | M/F | Death certificates | HR 1.04 (1.01, 1.07) | 8 |
| Thomas et al./2011 (44) | Finland | Cohort | 9.1 | T1DM | 38 | M/F | National Death Registry | HR 1.03 (1.01, 1.05) | 7 |
| Selvin et al. 2013 (47) | USA | Cohort | 18 | Middle-aged adults | 56.6 | M/F | Hospital surveillance | HR 0.98 (0.96, 0.99) | 9 |
| Isoyama et al. 2014 (48) | Sweden | Cohort | 1.9 | CKD | 56 | M/F | NR | HR 1.01 (0.98, 1.04) | 6 |
| Thomas et al./2015 (50) | Mixed countries | Case-cohort | 5 | T2DM | 66.9 | M/F | NR | HR 1.00 (1.00, 1.01) | 6 |
| Jung et al./2017 (51) | Korea | Cohort | 3.6 | Hemodialysis patients | 58.1 | M/F | NR | HR 1.00 (0.99, 1.01) | 5 |
| Dozio et al./2018 (52) | Italy | Cohort | 2 | Dialysis patients | 63.7 | M/F | NR | OR 1.04 (0.99, 1.09) | 6 |
| Ho et al./2018 (45) | USA | Cohort | 14.3 | General population | 62 | M/F | Follow-up with annual health history | HR 0.99 (0.99, 1.00) | 9 |
| Butcher et al./2019 (53) | Spain | Cohort | 6 | Older adults | 75 | M/F | National Death Index | HR 1.03 (1.00, 1.05) | 7 |
| Ebert et al./2020 (16) | Germany | Cohort | 12 | Men without DM or renal dysfunction | 65 | M | Health department of the city | HR 1.00 (0.99, 1.01) | 9 |
| Ebert et al./2020 (16) | Germany | Cohort | 12 | Women without DM or renal dysfunction | 64 | F | Health department of the city | HR 1.01 (0.99, 1.02) | 9 |
| Ebert et al./2020 (16) | Germany | Cohort | 12 | Men with DM or renal dysfunction | 65 | M | Health department of the city | HR 0.99 (0.98, 1.01) | 9 |
| Ebert et al./2019(16) | Germany | Cohort | 12 | Women with DM or renal dysfunction | 64 | F | Health department of the city | HR 1.00 (0.99, 1.01) | 9 |
| CVD mortality | |||||||||
| Semba et al./2009 (38) | Italy | Cohort | 4.5 | Older community-dwelling women | ≥65 | F | National Death Index | HR 1.04 (0.99, 1.09) | 7 |
| Nakashima et al./2010 (43) | Sweden | Prospective case-control | 3.4 | Hemodialysis patients | 67 | M/F | NR | HR 1.00 (0.99, 1.02) | 6 |
| Raposeiras-Roubín et al./2011 (54) | Spain | Cohort | 1.3 | Outpatients with CHF | 72 | M/F | Follow-up | HR 1.26 (1.09, 1.45) | 6 |
| Thomas et al./2011 (44) | Finland | Cohort | 9.1 | T1DM | 38 | M/F | National Death Registry | HR 1.06 (1.03, 1.09) | 7 |
| Ho et al./2018 (45) | USA | Cohort | 14.3 | General population | 62 | M/F | Follow-up with annual health history | HR 1.02 (1.00, 1.03) | 9 |
| Ebert et al./2020 (16) | Germany | Cohort | 12 | General population | 65 | M | Health department of the city | HR 0.99 (0.98, 1.00) | 9 |
| Ebert et al./2020 (16) | Germany | Cohort | 12 | General population | 64 | F | Health department of the city | HR 1.01 (0.99, 1.02) | 9 |
1
CHF, chronic heart failure; CKD, chronic kidney disease; CVD, cardiovascular diseases; DM, diabetes mellitus; NR, not reported; sRAGE, soluble receptor for advanced glycation end products; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.